Interferon Beta
drugOn this page
Also known as AvonexExtaviaHuman interferon betaInterf b 1aInterf b 1bInterfb1aInterferon beta naturalInterferon-betaRebif
Summary
Interferon Beta (CHEMBL2108510) is a phase-3 clinical-stage protein (ATC L03AB02) targeting IFNAR1; indicated across 14 conditions including neoplasm and intermediate uveitis.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- ATC class: L03AB02
- Targets: 1 (IFNAR1)
- Indications: 14 conditions
- Clinical trials: 62
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108510 |
| Name | Interferon Beta |
| Type | Protein |
| Max phase | 3 |
| ATC | L03AB02 |
Also known as: Avonex, Extavia, Human interferon beta, Interf b 1a, Interf b 1b, Interfb1a, Interferon beta, Interferon beta natural, Interferon-beta, Rebif, INTERFERON-BETA, INTERFERON BETA
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| IFNAR1 | interferon α/β receptor 1 | Agonist | 7.8 | 0.1% | P17181 |
| Interferon-α/β receptor | Agonist |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): IFNAR1.
Top Reactome pathways
16 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Cytokine Signaling in Immune system | 1 | IFNAR1 |
| Disease | 1 | IFNAR1 |
| Immune System | 1 | IFNAR1 |
| Infectious disease | 1 | IFNAR1 |
| Interferon alpha/beta signaling | 1 | IFNAR1 |
| Regulation of IFNA/IFNB signaling | 1 | IFNAR1 |
| Interferon Signaling | 1 | IFNAR1 |
| Potential therapeutics for SARS | 1 | IFNAR1 |
| SARS-CoV Infections | 1 | IFNAR1 |
| SARS-CoV-2 Infection | 1 | IFNAR1 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | 1 | IFNAR1 |
| SARS-CoV-2-host interactions | 1 | IFNAR1 |
| Respiratory Syncytial Virus Infection Pathway | 1 | IFNAR1 |
| Viral Infection Pathways | 1 | IFNAR1 |
| Evasion by RSV of host interferon responses | 1 | IFNAR1 |
| RSV-host interactions | 1 | IFNAR1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| cell surface receptor signaling pathway via JAK-STAT | 1 |
| response to virus | 1 |
| response to lipopolysaccharide | 1 |
| cellular response to interferon-alpha | 1 |
| cellular response to interferon-beta | 1 |
| type I interferon-mediated signaling pathway | 1 |
| cellular response to virus | 1 |
| positive regulation of cellular respiration | 1 |
| regulation of transcription by RNA polymerase II | 1 |
| positive regulation of metabolic process | 1 |
| cytokine-mediated signaling pathway | 1 |
| regulation of receptor signaling pathway via JAK-STAT | 1 |
| positive regulation of protein localization to nucleus | 1 |
Indications & clinical
Indications
14 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| intermediate uveitis | 3 | MONDO:0006806 | EFO:1000986 |
| multiple sclerosis | 3 | MONDO:0005301 | MONDO:0005301 |
| severe acute respiratory syndrome | 3 | MONDO:0005091 | EFO:0000694 |
| melanoma | 2 | MONDO:0005105 | EFO:0000756 |
| cutaneous neuroendocrine carcinoma | 1 | MONDO:0019210 | EFO:1001471 |
| glioblastoma | 1 | MONDO:0018177 | EFO:0000519 |
| oligoastrocytoma | 1 | MONDO:0016702 | EFO:0000630 |
| anaplastic astrocytoma | 1 | MONDO:0016684 | EFO:0002499 |
| chronic progressive multiple sclerosis | 1 | MONDO:0005284 | EFO:0003840 |
| relapsing-remitting multiple sclerosis | 1 | MONDO:0005314 | EFO:0003929 |
| gliosarcoma | 1 | MONDO:0016681 | EFO:1001465 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 62.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 15 |
| PHASE4 | 14 |
| PHASE2 | 14 |
| PHASE1 | 9 |
| PHASE3 | 8 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00037102 | PHASE4 | COMPLETED | Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis |
| NCT00037115 | PHASE4 | WITHDRAWN | Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. |
| NCT00101959 | PHASE4 | WITHDRAWN | Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects |
| NCT00146068 | PHASE4 | COMPLETED | EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis |
| NCT00179478 | PHASE4 | COMPLETED | Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis |
| NCT00202995 | PHASE4 | TERMINATED | Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS |
| NCT00246324 | PHASE4 | COMPLETED | Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis |
| NCT00317941 | PHASE4 | COMPLETED | Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif |
| NCT00771043 | PHASE4 | WITHDRAWN | A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a |
| NCT01085318 | PHASE4 | COMPLETED | Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial |
| NCT01333501 | PHASE4 | COMPLETED | Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms |
| NCT02019550 | PHASE4 | COMPLETED | Rebif® Rebidose® Versus Rebiject II® Ease-of-Use |
| NCT02234869 | PHASE4 | WITHDRAWN | Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy |
| NCT02254304 | PHASE4 | COMPLETED | Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ |
| NCT00211887 | PHASE3 | COMPLETED | Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx |
| NCT00344253 | PHASE3 | COMPLETED | Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis |
| NCT00428584 | PHASE3 | COMPLETED | RNF and Betaseron® Tolerability Study |
| NCT00473213 | PHASE3 | COMPLETED | Optimizing IFN Beta - 1B Dose |
| NCT01181115 | PHASE3 | COMPLETED | Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) |
| NCT01252355 | PHASE3 | TERMINATED | Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta |
| NCT02937285 | PHASE3 | COMPLETED | National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis |
| NCT04324463 | PHASE3 | COMPLETED | Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial |
| NCT06510426 | PHASE2 | RECRUITING | Early Interferon-beta Treatment for West-Nile Virus Infection |
| NCT00048347 | PHASE2 | COMPLETED | Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis |
| NCT00151801 | PHASE2 | UNKNOWN | Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients |
| NCT00217295 | PHASE2 | UNKNOWN | A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis |
| NCT00235989 | PHASE2 | COMPLETED | Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis |
| NCT00436826 | PHASE2 | COMPLETED | A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) |
| NCT00676715 | PHASE2 | COMPLETED | A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis |
| NCT00789685 | PHASE1/PHASE2 | COMPLETED | Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II |
| NCT00942591 | PHASE2 | COMPLETED | Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b |
| NCT01071083 | PHASE2 | COMPLETED | Treatment Interruption of Natalizumab |
| NCT01126177 | PHASE2 | COMPLETED | Comparing Efficacy and Safety of Inhaled SNG001 to Placebo |
| NCT01171209 | PHASE2 | COMPLETED | REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients |
| NCT01198132 | PHASE2 | COMPLETED | A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly |
| NCT01714089 | PHASE2 | WITHDRAWN | Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis |
| NCT01864148 | PHASE2 | COMPLETED | Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex |
| NCT00031083 | PHASE1 | COMPLETED | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas |
| NCT00299962 | PHASE1 | COMPLETED | Gene Therapy for Pleural Malignancies |
| NCT01119677 | PHASE1 | COMPLETED | A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Genes: IFNAR1
- Diseases: neoplasm, intermediate uveitis, multiple sclerosis, severe acute respiratory syndrome